Emergent BioSolutions
EBS
#6766
Rank
A$0.95 B
Marketcap
A$17.92
Share price
-1.24%
Change (1 day)
26.29%
Change (1 year)

Emergent BioSolutions (EBS) - Cash on Hand

Cash on Hand as of September 2025 : A$0.36 Billion

According to Emergent BioSolutions 's latest financial reports the company has A$0.36 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Emergent BioSolutions - Cash on Hand chart (from 2004 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31A$0.15 B-2.43%
2023-12-31A$0.16 B-82.64%
2022-12-31A$0.94 B18.83%
2021-12-31A$0.79 B-1.65%
2020-12-31A$0.80 B237.14%
2019-12-31A$0.23 B50.48%
2018-12-31A$0.15 B-30.26%
2017-12-31A$0.22 B-39.37%
2016-12-31A$0.37 B-11%
2015-12-31A$0.42 B23.48%
2014-12-31A$0.34 B70.47%
2013-12-31A$0.20 B47.49%
2012-12-31A$0.13 B-4.17%
2011-12-31A$0.14 B-15.52%
2010-12-31A$0.16 B46.97%
2009-12-31A$0.11 B-11.63%
2008-12-31A$0.12 B7.21%
2007-12-31A$0.12 B24.75%
2006-12-31A$96.94 M95.44%
2005-12-31A$49.6 M462.74%
2004-12-31A$8.81 M
2002-12-31A$8.68 M-24.32%
2001-12-31A$11.47 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Merck
MRK
A$27.42 B 7,319.14%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
A$0.25 B-29.96%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
A$6.69 B 1,710.34%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
A$0.87 B 137.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$22.55 B 6,003.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$3.31 B 797.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
A$15.84 M-95.71%๐Ÿ‡บ๐Ÿ‡ธ USA